Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Conditions
Keywords
First-in-Human, immunoPET agent, CD46 positive malignancy
Brief summary
CD46 is an exciting new therapeutic target in prostate cancer, with the antibody drug conjugate FOR46 under investigation in phase I clinical trials. The hypothesis of the study is that CD46 expression, measured via our novel imaging biomarker, is a characteristic feature of mCRPC, and particularly common in the most lethal forms of the disease including adenocarcinoma and Small-cell neuroendocrine carcinoma (SCNC). These data will provide crucial information about the feasibility of targeting cluster of differentiation 46 (CD46) in mCRPC, will be used guide the development of novel therapeutic and theranostic agents, to help develop treatments that improve outcomes for men with the most lethal forms of prostate cancer.
Detailed description
This single center imaging study involves one microdose of the imaging agent, followed by whole body PET imaging. Imaging data will be acquired in up to four PET studies to determine tumor and normal tissue uptake and dosimetry. PRIMARY OBJECTIVES: 1. To determine the optimal time point for imaging (based on analyzing the 4 scans of all participants using 89Zr-DFO-YS5 PET post-injection). (Cohort A) 2. To determine the optimal antibody dose for imaging using 89Zr-DFO-YS5 PET. (Cohort B). 3. To determine the sensitivity of metastatic lesion detection in mCRPC using 89Zr-DFO-YS5 PET as compared with conventional imaging (Cohorts C) SECONDARY OBJECTIVES: 1. To determine the safety of 89Zr-DFO-YS5. 2. To determine average organ uptake of 89Zr-DFO-YS5 (Cohort C). 3. To descriptively report the patterns of intra-tumoral uptake of 89Zr-DFO-YS5 on whole body PET, including by site of disease, uptake by tumor type, inter-tumoral and inter-patient heterogeneity, and tumor-to-background signal (Cohorts C). OUTLINE: Participants were originally assigned to 1 of 3 cohorts. Cohort B is closed to accrual. Enrollment into Cohort A and C are ongoing. Cohort A: PET imaging data will be acquired up to four times to determine tumor and normal tissue uptake and dosimetry. The optimized scan time will be used for imaging in Cohorts B and C. (CLOSED) Cohort B: A dose of cold, non-radiolabeled antibody administered will be varied to determine the optimal antibody dose for image quality. The optimized antibody dose will be used in Cohort C. Participants will be followed for an additional 4-5 weeks after dose administration to assess for adverse events. Cohort C: PET imaging will be acquired at the optimal time point and optimal antibody dose determined in Cohorts A & B, and have the option to obtain an repeat scan at the time of disease progression. All participants will be followed for up to 5 weeks after their first scan to assess for adverse events and will be followed-up until progression. At the time of progression, participants will have the option to receive a repeat scan.
Interventions
DRUG89Zr-DFO-YS5
3 mCi will be administered intravenously
BIOLOGICALYS5 antibody
20 or 50 mg administered intravenously
Imaging which combines a CT scan and a PET scan
Imaging which combines an MRI scan and a PET scan
Sponsors
Robert Flavell, MD, PhD
United States Department of Defense
Fortis Therapeutics, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participants must have histologically or cytologically confirmed metastatic, castration resistant prostate cancer (mCRPC). 2. Age \>=18 years 3. Eastern Cooperative Oncology Group (ECOG) performance status \< 2 (Karnofsky \>60%). 4. Demonstrates adequate organ function as defined below: 1. Total bilirubin \<1.5 X upper limit of normal (ULN). 2. Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase (SGOT)) \<= 3 X institutional upper limit of normal (ULN). 3. Alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase (SGPT)) \<= 3 X institutional ULN. 4. Serum creatinine \<=1,5 X institutional ULN or calculated creatinine clearance (Glomerular filtration rate (GFR)) \>= 60 mL/min, calculated using the Cockcroft-Gault equation. 5. Ability to understand a written informed consent document, and the willingness to sign it. 6. Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
Exclusion criteria
1. Patients who because of age, general medical, or psychiatric condition, or physiologic status cannot give valid informed consent. 2. Any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Optimal time point for imaging using 89Zr-DFO-YS5 PET post-injection (Cohort A) | Up to 7 days | For Cohort A, the optimal time point will be selected based on optimal maximun Standardized uptake value (SUVmax) of metastatic lesions, and ratio of SUVmax to blood pool. Due to the limited samples, the investigator will use all available lesions without considering the location of the lesions or the possible intra-correlation of the lesions from the same participant. |
| Optimal antibody dose for imaging using 89Zr-DFO-YS5 PET (Cohort B) | Up to 7 days | For Cohort B, the optimal dose of antibody will be selected based on the optimal SUVmax of metastatic lesions, and ratio of SUVmax to blood pool. Due to the limited samples, the investigator will use all available lesions without considering the location of the lesions or the possible intra-correlation of the lesions from the same participant. |
| Proportion of participants with metastatic lesions accurately detected in mCRPC using 89Zr-DFO-YS5 PET (sensitivity) (Cohort C) | Up to 24 months | Sensitivity is the probability that a test will indicate disease among those with the actual disease: True Positive / (True Positive + False Negative). Lesions will be graded on a semi-quantitative scale ranging from 1-5 as is common for 89Zr-antibody human imaging studies (1 = no uptake, 2 = probably no uptake, 3 = equivocal, 4 = probably positive, 5 = definitely positive). Using as a cut-off to 4 or 5 on the semi-quantitative scale, the sensitivity of 89Zr-DFO-YS5 PET will be descriptively reported on a lesion-per-lesion basis, using as reference standard staging scans including CT or MRI of the chest/abdomen/pelvis and whole body bone scan. The sensitivity estimate will be based on lesion level without considering the location of the lesions or the possible intra-correlation of the lesions from the same patient. |
| Median SUVmax (Cohort C) | Up to 24 months | The median and range of SUVmax across all metastatic lesions per participant will be descriptively reported using mediastinal blood pool and normal organ as background uptake values will be reported with range of SUVmax. |
| Average SUVmax (SUVmax-ave) (Cohort C) | Up to 24 months | The average SUVmax-ave across all metastatic lesions per participant will be descriptively reported using mediastinal blood pool and normal organ as background uptake values for all cohorts will be reported with 95% confidence intervals |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of participants with treatment-related Adverse Events | Up to 3 weeks after last dose administration, approximately 35 days | The frequency and severity of adverse events following Zr-DFO-YS5 injection will be descriptively reported, using CTCAE version 5.0 |
| Average organ uptake of 89Zr-DFO-YS5 (Cohort C) | Up to 24 months | Average organ uptake of 89Zr-DFO-YS5 on PET will be estimated. |
| Intra-tumoral uptake of 89Zr-DFO-YS5 by tumor type (Cohort C) | Up to 24 months | The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported |
| Intra-tumoral uptake of 89Zr-DFO-YS5 by Site of Disease (Cohort C) | Up to 24 months | The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported |
| Inter-tumoral heterogeneity (Cohort C) | Up to 24 months | The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported to assess for Inter-tumoral heterogeneity. |
| Inter-participant heterogeneity (Cohort C) | Up to 24 months | The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported to assess for Inter-participant heterogeneity |
| Tumor-to-background signal (Cohort C) | Up to 24 months | The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORRobert Flavell, MD, PhD
University of California, San Francisco
Outcome results
None listed